Sangamo Therapeutics (SGMOQ) Operating Expenses (2010 - 2025)

Sangamo Therapeutics has reported Operating Expenses for 16 years, with the latest figure at $52.4 million in Q4 2025.

• On a quarterly basis, Operating Expenses rose 56.32% year-over-year to $52.4 million in Q4 2025; TTM through Dec 2025 was $160.8 million, a 0.6% decrease from a year earlier, with the FY2025 full-year figure at $160.8 million, down 0.6% from the prior year.
• Operating Expenses was $52.4 million for Q4 2025 at Sangamo Therapeutics, up from $36.1 million in the prior quarter.
• The five-year high for Operating Expenses was $139.9 million in Q1 2023, with the low at $33.5 million in Q4 2024.
• Average Operating Expenses over 5 years is $69.0 million, with a median of $70.2 million recorded in 2021.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 90.39% in 2023, then plunged 71.29% in 2024.
• Over 5 years, Operating Expenses stood at $67.9 million in 2021, then climbed by 21.71% to $82.6 million in 2022, then fell by 22.42% to $64.1 million in 2023, then sank by 47.67% to $33.5 million in 2024, then jumped by 56.32% to $52.4 million in 2025.
• The last three Operating Expenses figures came in at $52.4 million (Q4 2025), $36.1 million (Q3 2025), and $36.2 million (Q2 2025), per Business Quant data.